About the Event

The Only Event Dedicated to Optimizing ADC Process Development & Accelerating Manufacturing to Stay Ahead of Shortening Timeframes

As the ADC industry grows more competitive and manufacturing timelines get shorter, don’t let your processes hold you back.

With more ADC programs entering the clinic and commercial focus intensifying, this year's 3rd ADC Process Development Summit returns to spotlight the process innovations needed to deliver high-quality ADCs efficiently and reliably.

Providing a technical program built for experts in process development, CMC, manufacturing, and regulatory strategy, this is the only ADC meeting taking a deep dive into the operational details. From bioconjugation and purification to technology transfer and drug product scale-up, get the insights to streamline your processes and deliver more homogenous & high-quality ADCs faster.

“I am excited to engage with colleagues from diverse functions and backgrounds, exchanging insights into the latest advancements in ADC process development. Together, by sharing our expertise and fostering collaboration, we can enhance the ADC pipeline and ensure the continued safety and well-being of patients worldwide”

Laurencia Zongo, Scientist, Purification Process Sciences, AstraZeneca
Expert Speaker, 2025

Unmissable Agenda Highlights:

54266 Favicon

Overcome impurity challenges by exploring new methods to identify, characterize, and control process-related variants and degradation products with Northeastern University

54266 Favicon

Define CQA-driven specifications to guide phase-appropriate process development and accelerate tech transfer with ADC Therapeutics and AstraZeneca

54266 Favicon

Advance drug product development by tackling dosage form and SKU considerations, rapid lyophilization cycle development, and comparability strategies with AbbVie and Exelixis

54266 Favicon

Discuss single-use vs. stainless steel equipment choices for conjugation, purification, and scale-up in dedicated roundtables with CDMO and process leaders

54266 Favicon

Align process development with regulatory CMC expectations to balance early-phase flexibility with compliant strategies, with Merck and leading regulatory experts

New speaking companies for 2025:

Merck_Logo.svg
ADC Therapeutics
Daiichi Sankyo
Genentech
Santa Ana Bio